Carelabs Co., Ltd. Overview
Carelabs is a Seoul-based, KOSDAQ-listed digital health and medical-aesthetics platform group controlled since January 2023 by Wonik Holdings, the holding company of a mid-sized Korean semiconductor and battery-equipment conglomerate. Its economic engine today is Babitalk, a medical-beauty information and review platform that generated about KRW 36.8 bn of revenue and KRW 7.3 bn of operating profit in FY2025 and is being absorbed into the parent in December 2026. Around it sit a shrinking parent-level B2B services business (performance marketing for clinics, hospital CRM software, smart-hospital kiosks, medical recruiting), a profitable pharmacy-software subsidiary (EDB), a structurally loss-making telemedicine and booking app (Goodoc), and early-stage bets on oncology information (Heal-O) and senior care. Consolidated revenue has drifted from KRW 93.9 bn (FY2021) to KRW 81.7 bn (FY2025) with recurring operating losses since FY2022. The equity story rests on Babitalk's inbound medical-tourism opportunity and Korea's December 2026 telemedicine legalisation, offset by governance, scale and liquidity concerns.
Company's own description
In its corporate materials Carelabs presents itself as a healthcare and beauty-care platform company for everyone, providing comprehensive healthcare IT services that include clinic information services, clinic customer-management software and digital-marketing solutions [S1][S3]. Its IR materials and press releases describe a "digital healthcare value chain" connecting patients, medical staff, hospitals and pharmacies through the parent and three subsidiaries (Goodoc, Babitalk, EDB) [S17][S25]. At the March 2026 AGM management framed 2026 as a turnaround year built on entry into senior care, AI-enhanced services and a "One CareLabs" integration concept [S22].
Independent characterisation
Carelabs is best understood as a holding-style portfolio of five distinct businesses with very different economics:
-
Medical-aesthetics marketplace (Babitalk) — a two-sided platform monetised primarily through advertising and performance fees paid by plastic-surgery, dermatology and aesthetic clinics. It is the only clearly profitable, growing engine (FY2025 revenue KRW 36.8 bn, operating profit KRW 7.3 bn, ~3,300 hospital/doctor network, 10 million cumulative downloads) [S29][S17].
-
Parent-level B2B services for clinics — performance/digital-marketing agency services, hospital CRM software ("Uno CRM"/Care CRM), smart-hospital solutions (kiosk payment, certificate issuance, queue management, RFID, QR), and the Medijob/Yobosarang recruiting platforms [S3][S25]. Parent-only revenue fell from KRW 41.0 bn (FY2024) to KRW 33.8 bn (FY2025) and a further 36.2% YoY in Q1 2026 [S1][S12].
-
Pharmacy software (EDB, 51% owned) — QR-code prescription-security systems and pharmacy claims software; Q1 2026 revenue KRW 3.5 bn (+24% YoY) with operating profit up 255% [S7][S17].
-
Consumer healthcare access app (Goodoc, 88.74% owned) — clinic search, booking and walk-in registration, telemedicine and prescription transfer. Revenue collapsed from about KRW 12.1 bn (2021) to KRW 1.0 bn (2024 and 2025); the entity has been in full capital impairment since end-2021 [S7].
-
New bets — Heal-O oncology-journey platform (launched Aug 2025) and a planned senior-care facility on land acquired in Seoul's Godeok-Gangil district (2025) [S26][S30].
Revenue model mix
| Revenue type | Main business lines | Characterisation |
|---|---|---|
| Advertising / performance fees from clinics | Babitalk, Goodoc, Heal-O (potential) | Platform/marketplace revenue; dominant and highest margin |
| Agency / service fees | Parent digital-marketing division | Project and performance-based services; declining |
| Software licences / subscriptions | Hospital CRM, EDB pharmacy software, smart-hospital solutions | Recurring B2B SaaS-like revenue |
| Hardware-linked solutions | Smart-hospital kiosks, tablets | Equipment plus service; minor cost of sales |
| Recruitment fees | Medijob, Yobosarang | Job-posting / matching fees |
Exact revenue split by revenue type is not publicly disclosed in sources reviewed. Aggregator data based on Q2 2026 filings put the reported segment mix at roughly 50% healthcare media platforms, 26% solutions and 24% marketing [S5]. Cost of revenue is negligible (KRW 0.17–0.94 bn per quarter in 2025–26) because the company presents most expenses within SG&A [S13].
Value-chain position, customers and end markets
Carelabs sits in the demand-generation and workflow layer between consumers and providers. Paying customers are overwhelmingly B2B: private plastic-surgery and dermatology clinics (Babitalk), primary-care clinics and hospitals (Goodoc, CRM, smart hospital), pharmacies (EDB), and healthcare employers including long-term-care institutions (Medijob, Yobosarang). Consumers use most services free of charge. End markets are Korean medical aesthetics, inbound medical tourism (initially Japan), primary care access and telemedicine, pharmacy IT, healthcare staffing and, prospectively, senior care.
Strategy
Stated strategy themes (2026)
Turnaround in 2026: management told shareholders 2026 should lay the foundation for a turnaround, with responsibility for strengthening the competitiveness and profitability of core businesses [S22].
Senior care entry: entering rehabilitation- and care-centred senior care in response to super-ageing, building synergies with digital-health capabilities [S22].
"One CareLabs": linking data accumulated in Goodoc and Babitalk with AI to connect services across the patient journey (search–selection–experience–management) [S22][S24].
Babitalk as core global business: the October 2026 merger is explicitly intended to simplify decision-making, cut duplicated overhead and concentrate resources on Babitalk's global medical-tourism business, including integrated marketing with the parent's performance-marketing unit, more languages and AI features [S21][S73].
Initiative register (last 24 months)
| Date | Initiative | Type | Target / scope | Source |
|---|---|---|---|---|
| Sep 2024–Feb 2025 | Sale of Yeoksam-dong property interest to Wonik affiliates | Balance-sheet restructuring | About KRW 74.5–75.4 bn proceeds | [S8][S10] |
| Jul 2025 | Yobosarang acquisition | Business extension | Care-worker recruiting | [S25] |
| Aug 2025 | Babitalk Japan web service | International expansion | Japanese consumers seeking Korean procedures | [S28] |
| Aug 2025 | Heal-O launch | New platform | Cancer patients and caregivers | [S26] |
| Sep–Oct 2025 | Godeok-Gangil land purchases | Senior-care infrastructure | Planned senior-care building | [S30][S31] |
| Nov 2025 | KRW 10.0 bn Goodoc recapitalisation | Subsidiary support | Restore Goodoc equity | [S7] |
| Mar 2026 | New business purposes (cosmetics, health foods, etc.) | Optionality | Not specified | [S23] |
| Apr 2026 | Heal-O AI upgrade | Product | AI answers, nursing-hospital search | [S27] |
| H1 2026 | Babitalk AI search; Japanese app | Product | Review-based AI search | [S17] |
| Jul 2026 | C-level hires (CSO, Goodoc CTO) | Organisation | Strategy and AI/data | [S24] |
| Oct 2026 | Babitalk absorption | Restructuring | Merger date 18 Dec 2026 | [S18] |
Sustainability / ESG commitments
None disclosed in sources reviewed.
Financial targets / guidance
No quantitative medium-term targets or formal guidance were identified. Historical note: in 2020 a broker expected record operating profit of KRW 7 bn on KRW 78 bn sales; actual FY2020 operating profit was KRW 6.0 bn [S72][S42].
Products & Services
Healthcare media platforms
Babitalk (바비톡) — medical-beauty platform
-
Description: information, review and booking platform for plastic surgery and non-invasive aesthetic procedures (lifting, fillers, botulinum toxin, lasers, skin boosters) [S4][S28].
-
Scale: 10 million cumulative downloads (2026); network of about 3,300 hospitals and doctors; FY2025 revenue KRW 36.8 bn, operating profit KRW 7.3 bn [S17][S29].
-
Recent capabilities: AI search built on review big data, described by the company as an industry first (2026); Japanese web service (Aug 2025) and Japanese app using AI natural-language translation; Japanese-consultation indicators per clinic and direct links to clinic consultation channels [S17][S28].
-
Customers: aesthetic clinics (payers), consumers in Korea and Japan (users).
-
Pricing: advertising and performance-based fees; specific tariffs not publicly disclosed.
-
Launch: Dec 2012 [S2].
Goodoc (굿닥) — clinic search, booking and telemedicine
-
Description: search, review, booking, walk-in registration, telemedicine (video/voice), and prescription transmission to partner pharmacies via a pharmacy admin tool; uses Health Insurance Review & Assessment Service (HIRA) data for clinic information [S4][S46].
-
Products within Goodoc: consumer app; clinic registration tablets; QR check-in kiosks deployed at large hospitals during COVID-19; AI health Q&A service ("24-hour Health Talk") [S69][S46].
-
Scale data points: 7.5 million cumulative downloads and about 1.5 million average MAU (Oct 2021); MAU up 25% YoY in Q1 2026 (absolute figure not disclosed) [S69][S17].
-
Certifications: ISMS certification for the Goodoc service platform, valid 7 Feb 2024 – 6 Feb 2027 [S46].
-
Monetisation: clinic subscriptions/advertising, kiosk and tablet services, prescription-related fees; revenue only KRW 1.0 bn in FY2025 [S7].
-
Launch: May 2012; spun off July 2020 [S2].
Heal-O (힐오) — oncology journey platform
-
Description: cancer-information platform covering symptoms, diagnosis, treatment and recovery for all cancer types, with eight major cancers (liver/biliary, thyroid, colorectal, gastric, breast, prostate, pancreatic, lung) featured; communities by cancer type and stage; "find a top doctor" search using HIRA data; cancer encyclopedia [S26].
-
April 2026 upgrade: AI paper summaries and doctor-selection guide in the doctor search; separate "clinician answer" and "AI answer" Q&A options; new search for cancer-specialised long-term-care hospitals [S27].
-
App store listing cites information on more than 6,000 doctors [App Store listing referenced in S26 context].
-
Pricing: free to users; monetisation model not publicly disclosed.
-
Launch: 27 Aug 2025 [S26].
Medijob (메디잡) and Yobosarang (요보사랑) — healthcare recruiting
-
Medijob: recruiting platform for doctors, nurses, pharmacists, dental hygienists and other medical staff; acquired as a business in Feb 2019 [S2][S25].
-
Yobosarang: care-worker (요양보호사) matching platform acquired from Korea Senior Research Institute in July 2025, used by about 25,000 care workers and 1,500 care institutions at acquisition; integrated posting with Medijob launched May 2026 [S25].
Solutions
| Product | Description | Customers | Source |
|---|---|---|---|
| Care CRM / Uno CRM | Clinic customer-management software combining front-desk workflow, patient management and marketing; configurable by clinic size and specialty; integrates with insurance claims and other applications | Clinics, especially non-reimbursed specialties | [S3][S26] |
| Smart Hospital solutions | Kiosk-based unattended payment, certificate issuance, intelligent queueing, waiting-time display, RFID, QR platform, online certificates; includes consulting | Hospitals | [S3] |
| EDB prescription-security system | QR-code based prescription-security system and pharmacy claims software | Pharmacies, clinics | [S4] |
Marketing
Digital Marketing Division: performance-marketing agency for clients in the medical sector, using targeting to connect clinics with prospective patients [S3][S59]. The October 2026 Babitalk merger is intended to integrate Babitalk platform advertising with this external performance-marketing offer [S73].
Pipeline / planned offerings
Senior-care facility: building planned on Godeok-Gangil commercial land parcel 1-2 (5,462 m², Gangdong-gu, Seoul), acquired for KRW 75.11 bn; management describes entry into rehabilitation- and care-centred senior care [S30][S22].
Consumer products: March 2026 article amendments added manufacturing (including contract manufacturing) and distribution of foods, health-functional foods, cosmetics, beauty goods, quasi-drugs and sundries [S23]. No product launches identified.
Social-dating business (acquired H2 2018), BNK Lab (merged into parent), BeautySocial Inc. (US), Eunogo Pte. Ltd. (Singapore), Uno Beauty, Approdi, Vital Labs (merged into Goodoc), and e-commerce initiatives from 2019 [S2][S40][S63]. Their current status is not disclosed in sources reviewed.
Financial Narrative
Income statement (consolidated)
Sources: FY2023–FY2025 audited figures [S1]; FY2021–FY2022 [S14][S43][S5]; EPS [S11]; dividend yield nil [S5]. Margins derived. FY2025 net income is KRW 19.51 bn on the company IR page (audited) versus KRW 19.47 bn in the February 2026 preliminary filing [S9]; the audited figure is used.
Gross profit: not meaningful; Carelabs reports expenses by nature, and cost of revenue was only KRW 0.17–0.94 bn per quarter in 2025–26, implying gross margin above 95% [S13].
EBITDA: not publicly disclosed in sources reviewed.
Pre-tax income: not publicly disclosed in sources reviewed.
Diluted EPS: not publicly disclosed in sources reviewed.
Revenue CAGR FY2021–FY2025: -3.4% (derived).
Longer history (context)
Sources: [S40][S41][S42][S43][S1][S14].
Quarterly trajectory (consolidated)
Sources: Q1 2025 [S15]; Q2 2025–Q1 2026 [S13]; Q2 2025 net income [S14]; Q2 2026 revenue and operating income derived from H1 2026 totals (revenue KRW 37.9 bn, operating loss KRW 0.048 bn) [S7]. H1 2026 net loss was roughly KRW 1.5 bn [S6].
Balance sheet
Sources: consolidated and separate totals [S1]; separate line items [S12]. Ratios derived. Consolidated cash, total debt split, goodwill and working capital are not publicly disclosed in sources reviewed. At end-2024 consolidated liabilities were KRW 88.3 bn; the February 2025 receipt of property proceeds allowed repayment of most parent borrowings. Retained earnings stood at about KRW -37.6 bn (accumulated deficit) as of the latest period on one aggregator [S5 context: Chickstock], and at about KRW -45 bn in early 2025 [S8]. The parent's separate cash fell further to KRW 6.5 bn at end-March 2026 while PP&E rose to KRW 27.1 bn, consistent with progress payments on the Godeok land [S12].
Paid-in capital was about KRW 9.8 bn at FY2025 [S64].
Cash flow
Operating cash flow, capex, free cash flow, dividends paid and buybacks are not publicly disclosed in sources reviewed. Qualitatively:
-
No dividends have been paid in the period reviewed [S5].
-
No share-buyback authorisation was identified; treasury shares are about 0.07% of shares [S5].
-
Investing cash flows in FY2025 were dominated by receipt of about KRW 74.5–75.4 bn of property-sale proceeds (KRW 14.9 bn deposit in 2024, KRW 59.6 bn balance in Feb 2025) and by deposits/instalments on the Godeok land [S8][S12].
-
Financing outflows in FY2025 included repayment of parent short-term borrowings (KRW 9.0 bn) and most of the KRW 34.0 bn current portion of long-term debt [S12].
Ratios
ROE, ROA and asset turnover for FY2024–FY2025 derived using average balances [S1]. Separate ROA [S11]. Aggregator TTM ROE was -10.9% in October 2026 [S5]. ROIC, current ratio (consolidated), net debt/EBITDA, interest coverage and cash conversion cycle are not publicly disclosed in sources reviewed; one aggregator reports a current ratio of 222.1% on a separate basis [S66].
Commentary on trends and inflections
Growth stalled after the pandemic peak: Revenue rose from KRW 39.3 bn (FY2017) to KRW 93.9 bn (FY2021), helped by acquisitions and COVID-era telemedicine demand, then declined about 13% to FY2025. Goodoc's revenue collapse (KRW 12.1 bn to 1.0 bn) and the shrinking parent marketing business explain most of the decline; Babitalk grew strongly over the same period [S7][S29].
Losses peaked in FY2023: The operating loss of KRW 11.6 bn in FY2023 narrowed to KRW 2.9 bn in FY2025 through cost cuts; the parent's separate management expenses fell from KRW 31.8 bn (FY2024) to KRW 25.5 bn (FY2025) [S12].
FY2025 profit is non-recurring: The KRW 19.5 bn net profit stems from a KRW 25.9 bn gain on the Yeoksam-dong property sold to Wonik affiliates; the company itself attributed the swing to efficiency gains and non-operating income from the asset transfer [S9][S10].
2026 relapse: H1 2026 revenue fell 20.3% YoY to KRW 37.9 bn and the company slipped back to a small operating loss [S7]. Parent-only revenue fell 36.2% YoY in Q1 2026 (KRW 6.7 bn versus 10.5 bn), indicating the decline is concentrated in parent-level services rather than Babitalk [S12]. Management has not publicly provided a detailed explanation for the Q4 2025 and Q2 2026 revenue drops.
Balance-sheet reset, then re-levering into property: FY2025 liabilities fell 63% to KRW 32.8 bn, but the company committed KRW 75.11 bn to Godeok land parcel 1-2 alone; the payment schedule is not disclosed in sources reviewed.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Ownership | Activity |
|---|---|---|---|
Wonik Holdings Co., Ltd. | Parent (largest shareholder) | 32.73% of Carelabs (planned increase to 33.76%) | Wonik Group holding company |
Carelabs Co., Ltd. | Listed company | — | Digital marketing, CRM, smart hospital, Medijob, Yobosarang, Heal-O, senior-care project |
Babitalk Co., Ltd. | Subsidiary (to be merged 18 Dec 2026) | 100% per merger filing (1,015,239 shares); 98.71% per Sept 2026 press | Medical-beauty platform |
Goodoc Co., Ltd. | Subsidiary | 88.74% (1,446,545 shares) | Booking, registration, telemedicine |
EDB Co., Ltd. | Subsidiary | 51% | Pharmacy prescription-security and claims software |
Segment (Q2 2026) Overview
| Segment (Q2 2026) | Contents (analyst mapping) | Share of revenue (%) | Derived Q2 2026 revenue (KRW Bn) |
|---|---|---|---|
Healthcare media platform | Babitalk, Goodoc, Heal-O, Medijob/Yobosarang (likely) | 50 | 8.7 |
Solutions | EDB pharmacy software, hospital CRM, smart hospital | 26 | 4.5 |
Marketing | Parent digital-marketing agency | 24 | 4.2 |
Revenue by Segment
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Consolidated revenue (KRW Bn) | 93.90 | 87.61 | 81.83 | 83.19 | 81.69 |
Carelabs parent revenue, separate (KRW Bn) | — | — | 37.24 | 41.03 | 33.82 |
Babitalk revenue (KRW Bn) | — | — | — | — | 36.80 |
Goodoc revenue (KRW Bn) | 12.10 | 7.80 | 4.50 | 1.00 | 1.00 |
EDB, other and eliminations, derived residual (KRW Bn) | — | — | — | — | 10.07 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Babitalk operating profit (KRW Bn) | — | — | 7.30 |
Carelabs parent operating profit, separate (KRW Bn) | -3.98 | -4.16 | -5.67 |
Goodoc net profit (KRW Bn) | — | 2.80 | — |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 93.90 | 87.61 | 81.83 | 83.19 | 81.69 |
Revenue growth YoY (%) | 22.5 | -6.7 | -6.6 | 1.7 | -1.8 |
Operating income (KRW Bn) | 3.28 | -6.38 | -11.60 | -4.46 | -2.88 |
Net income (KRW Bn) | 1.24 | -26.39 | -23.87 | -19.67 | 19.51 |
Basic EPS, attributable (KRW) | 73 | -1,434 | -1,260 | -1,045 | — |
Dividend per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Operating margin (%) | 3.5 | -7.3 | -14.2 | -5.4 | -3.5 |
Net margin (%) | 1.3 | -30.1 | -29.2 | -23.6 | 23.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Metric | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 39.34 | 54.38 | 68.30 | 76.67 | 93.90 | 87.61 | 81.83 | 83.19 | 81.69 |
Operating income (KRW Bn) | 6.26 | 5.07 | 3.62 | 6.00 | 3.28 | -6.38 | -11.60 | -4.46 | -2.88 |
Net income (KRW Bn) | 5.13 | 3.85 | 0.53 | 4.50 | 1.24 | -26.39 | -23.87 | -19.67 | 19.51 |
Income Statement (Quarterly)
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 23.07 | 22.52 | 21.16 | 14.95 | 20.54 | 17.36 |
Operating income (KRW Bn) | 0.84 | 2.58 | -0.59 | -5.71 | 0.67 | -0.72 |
Net income (KRW Bn) | 25.45 | -0.73 | — | — | — | — |
R&D expense (KRW Bn) | — | 0.39 | 0.40 | 0.68 | 0.39 | — |
Balance Sheet and Margin Analysis (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total assets, consolidated (KRW Bn) | 162.20 | 143.26 | 107.43 |
Total liabilities, consolidated (KRW Bn) | 87.13 | 88.28 | 32.80 |
Total equity, consolidated (KRW Bn) | 75.07 | 54.98 | 74.63 |
Liabilities-to-equity, consolidated (%) | 116.1 | 160.6 | 43.9 |
Total assets, separate (KRW Bn) | 138.87 | 118.11 | 83.96 |
Total liabilities, separate (KRW Bn) | 59.06 | 65.81 | 7.72 |
Cash and equivalents, separate (KRW Bn) | 5.9 | 14.5 | 9.7 |
Short-term borrowings, separate (KRW Bn) | 10.0 | 9.0 | 0.0 |
Current portion of long-term debt, separate (KRW Bn) | 6.1 | 34.0 | 1.2 |
Assets held for sale, separate (KRW Bn) | 60.7 | 48.7 | 0.0 |
Property, plant and equipment, separate (KRW Bn) | 2.7 | 10.7 | 26.1 |
Intangible assets, separate (KRW Bn) | 5.8 | 3.0 | 3.3 |
Investments in subsidiaries/associates, separate (KRW Bn) | 33.1 | 22.2 | 31.8 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansReturns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, consolidated (%) | — | — | — | -30.3 | 30.1 |
ROA, consolidated (%) | — | — | — | -12.9 | 15.6 |
ROA, separate, per FnGuide (%) | 1.50 | -10.56 | -17.88 | -20.39 | — |
Asset turnover, consolidated (x) | — | — | — | 0.54 | 0.65 |
Revenue by Region
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Korea revenue, derived as ~100% of consolidated (KRW Bn) | 81.83 | 83.19 | 81.69 |
Share Price
| Metric | Jun 2020 | Jan 2023 | Aug 2025 | Mar 2026 | Aug 2026 | Oct 2026 |
|---|---|---|---|---|---|---|
Share price (KRW) | 18,750 | 8,450 | 1,830 | 2,390 | 1,925 | 2,015 |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation | KRW 39.1 bn | KRW 2,015 × ~19.41 M shares [S5][S13] |
P/E (FY2025) | ~2.0x | Distorted by one-off gain; one aggregator showed 2.02x TTM earlier in 2026 [S58] |
P/B | 0.59x | [S5] |
EV/Sales | not computed | — |
Price/Sales (FY2025) | 0.48x | KRW 39.1 bn / KRW 81.69 bn |
Analyst Conclusions
Management guidance and consensus
No quantitative guidance or consensus forecasts are available. Management's qualitative messages are: 2026 as a turnaround-foundation year; growth from Babitalk (including Japan) and EDB; expansion into senior care; and AI-led product upgrades [S22][S17].
Bull case
-
Babitalk is undervalued inside the group. A business with KRW 36.8 bn revenue and KRW 7.3 bn operating profit in FY2025, growing past KRW 10 bn per quarter, is worth more on peer-implied multiples than the whole group's ~KRW 39 bn market cap; the merger into the parent makes this value directly attributable to listed shareholders [S29][S17][S18].
-
Demand tailwind from medical tourism. Foreign patients doubled to 2.01 million in 2025, with dermatology and plastic surgery leading growth; Japanese-language services position Babitalk for Korea's second-largest source market [S50][S28].
-
Cleaner balance sheet plus sponsor support. Parent liabilities fell to KRW 7.7 bn, and Wonik Holdings and the CEO are buying shares, signalling the group will continue backing the company [S1][S6].
Bear case
-
Structural decline outside Babitalk. Parent revenue fell 36.2% YoY in Q1 2026 and group revenue fell 20.3% in H1 2026; Goodoc remains in capital impairment despite KRW 20 bn of injections [S12][S7].
-
Capital allocation risk. Committing KRW 75.11 bn (52.43% of then assets) to land for an unproven senior-care business, while parent cash is single-digit KRW billions, raises funding and return risks [S30][S12].
-
Competitive and regulatory pressure. Gangnam Unni is larger, more profitable and further ahead in Japan; telemedicine platforms face conduct and advertising restrictions just as Goodoc lags Doctor Now [S52][S53][S49][S54].
Catalysts and monitorables (next 12 months)
-
Q3 2026 results (expected 12 Nov 2026) and explanation of the revenue decline [S57].
-
EGM on 26 Nov 2026 (articles amendment) and completion of the Babitalk merger on 18 Dec 2026 [S20][S18].
-
Telemedicine law implementation (expected late Dec 2026) and Goodoc's response [S48].
-
Disclosure of Godeok land payment schedule, construction financing and senior-care business plan.
-
Babitalk Japan traction metrics (users, partner clinics, revenue).
-
Wonik Holdings' stake changes and any further related-party transactions.
-
Market capitalisation versus the KRW 30 bn KOSDAQ threshold applying from 2027 [S6].
-
FY2026 annual report (March 2027): segment detail, cash-flow statement and impairment testing.
Analyst verdict
Carelabs is a small, controlled holding-style company whose listed value is now largely a claim on one good business. Babitalk is profitable, growing and strategically well placed to capture the extraordinary rise in foreign demand for Korean aesthetic medicine. Its FY2025 operating profit of KRW 7.3 bn compares with a group market capitalisation of roughly KRW 39 bn, and the December 2026 merger removes a layer between Babitalk's cash flows and public shareholders. On that narrow lens the stock screens as deeply undervalued at about 0.6x book and 0.5x sales.
The difficulty is everything around Babitalk. Group revenue has fallen for most of the last four years, the parent's service businesses are contracting sharply, and Goodoc has absorbed capital while its revenue collapsed. FY2025's headline profit came from selling property to sister companies, not from operations, and H1 2026 slipped back into an operating loss. Management has simultaneously committed a sum comparable to half of its then-assets to land for a senior-care venture with no disclosed business plan or funding structure, at a time when parent cash was below KRW 10 bn. Governance also deserves a discount: control sits with a sponsor whose interests extend across the Wonik Group, intra-group transactions have been used to fund the company, and executive leadership has been concentrated in the controlling family.
Overall, the evidence supports a cautious, event-driven stance rather than a fundamental long-term conviction. The investment case improves materially if (1) Babitalk's growth and margins are sustained after the merger and become visible in segment reporting, (2) the Godeok project is financed without straining the parent or diluting shareholders, and (3) losses at Goodoc and the parent are contained. Absent clear progress on these points by the FY2026 annual report, the persistent valuation discount is likely to remain justified. Data gaps (cash flow, segment profits, risk disclosures) should be closed through DART filings before any position is taken.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Age |
|---|---|---|---|---|
Lee Min-kyung (이민경) | CEO and inside director, Carelabs; director of Goodoc, Babitalk, EDB | CSO and director from Jan/Feb 2023; CEO from Jan 2025; re-elected Mar 2026 | Fine arts and crafts graduate of a US art university; manager at CMS Lab (medical cosmetics) Feb 2014–Feb 2019; M&A head, Wonik Holdings strategy office Mar 2019–Jan 2023; eldest daughter of Wonik founder-chairman Lee Yong-han | 37 (Sep 2026 press) |
Jang Young-ju (장영주) | CEO, Goodoc; Carelabs director | Carelabs board from Mar 2025; Goodoc CEO from Nov 2025 | — | 44 |
Kim Ji-woong (김지웅) | Chief Strategy Officer, Carelabs | Appointed Jul 2026 | Formerly Amazon and Toss Bank | — |
Lee Won-hee (이원희) | CTO, Goodoc | Appointed Jul 2026 | Formerly Coupang and Samsung Electronics | — |
Shin Jung-in (신정인) | CEO, Babitalk | Current | — | — |
Oh Se-jin (오세진) | CSO, Babitalk | Current (2025) | — | — |
Kim Ju-sung (김주성) | Outside director, Carelabs | Re-elected Mar 2026 | — | — |
Ji Myung-chan (지명찬) | Standing statutory auditor, Carelabs | Re-elected Mar 2026 | — | — |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change |
|---|---|
Nov 2018 | Park Kyung-deuk appointed CEO (co-CEO with Kim Dong-soo) |
Dec 2019 | Park Kyung-deuk becomes sole CEO |
Jan 2023 | Shin Jong-hyun appointed CEO upon Wonik takeover |
Jan 2025 | Lee Min-kyung succeeds Shin Jong-hyun as CEO |
Nov 2025 | Jang Young-ju appointed Goodoc CEO |
Mar 2026 | Outside-director changes filed; CEO re-elected; audit-committee clause deleted from articles (company uses a standing auditor) |
Jul 2026 | New CSO (parent) and CTO (Goodoc) |
Major Shareholders
| Holder | Shares | Stake (%) | Note |
|---|---|---|---|
Wonik Holdings | 6,353,442 | 32.73 | Average cost about KRW 12,234/share (KRW 77.7 bn total); 200,000-share open-market purchase announced from 7 Sep 2026, which would lift the stake to 33.76% |
Lee Min-kyung (CEO) | 53,472 | 0.28 | Bought on market 8 Jun 2026 at about KRW 1,867 |
Treasury shares | — | 0.07 | — |
Competitive Landscape
Competitors by Segment
| Business | Competitor | Description | Latest disclosed scale |
|---|---|---|---|
Medical aesthetics platform | Healing Paper (Gangnam Unni) | Market leader in aesthetics information; Japan subsidiary (acquired Lukumo, 2020); Thai-language "UNNI" | FY2024 revenue KRW 53.0 bn, operating profit KRW 12.9 bn; Series C KRW 42.8 bn (Feb 2025) at about KRW 580–600 bn valuation |
Medical aesthetics platform | Fastrain (Yeoshin Ticket) | Aesthetic-procedure ticketing platform | — |
Telemedicine | Doctor Now | Largest telemedicine platform | 1.45 million consultations in H1 2026; 8,600 partner institutions; over KRW 60 bn raised cumulatively |
Booking / registration | B-Bros (Ddocdoc) | Clinic booking/registration; UBcare is largest shareholder (37.8% in 2022) | 7 million members (2022); cumulative funding KRW 38.8 bn through Series D |
Telemedicine | Merakiplace (My Doctor / 나만의닥터) | Telemedicine app | FY2024 revenue about KRW 0.8 bn (secondary source) |
Health platforms | Kakao Healthcare | Big-tech health data and platforms | — |
Hospital apps / insurance claims | Lemon Healthcare | Hospital apps, paperless insurance claims | — |
EMR / pharmacy software | UBcare (GC group) | EMR leader; pharmacy software; owner of B-Bros stake | — |
Clinic CRM | Meta Labs (Meta S&C) | CRM for non-reimbursed specialty clinics (hair-loss, diet), listed | FY2025 revenue KRW 81.4 bn, operating loss KRW 7.1 bn (group, incl. distribution) |
Healthcare recruiting / generic | Generic job portals and specialist platforms | — | — |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | Carelabs (FY2025) | Babitalk standalone (FY2025) | Healing Paper (FY2024) | Meta Labs (FY2025) |
|---|---|---|---|---|
Revenue (KRW Bn) | 81.69 | 36.80 | 53.00 | 81.40 |
Operating income (KRW Bn) | -2.88 | 7.30 | 12.90 | -7.10 |
Operating margin (%) | -3.5 | 19.8 | 24.3 | -8.7 |
Revenue growth (%) | -1.8 | — | ~20 | 112 |



